• English
  • Eesti

    CAT meeting

    09.05.2017
    Printer-friendly version

    The Committee for Advanced Therapies (CAT) reviews the quality, safety, and efficacy of advanced-therapy medicinal products (ATMP) and monitors scientific developments in the field. ATMPs are medicines for human use that are made from genes and cells or tissues and include gene therapies, somatic cell therapy medicines, tissue-engineered products, and combined ATMPs.

    The committee meets at the European Medicines Agency (EMA) and participation is open to all experts of National Competent Authorities (NCA).

    The CAT’s main responsibility is to prepare a draft opinion on each ATMP application submitted to the EMA, before the Committee for Medicinal Products for Human Use (CHMP) adopts a final opinion on the granting, variation, suspension or revocation of a marketing authorisation for the medicine concerned. At the request of the EMA Executive Director or the European Commission, the CAT can also draft an opinion on any scientific issues related to ATMPs.

    The CAT members are appointed for a renewable period of three years.

    The Strategic Review and Learning Meeting of CAT will take place on 15-17 November 2017.